New Drug Approvals (Original) — January 22, 2026

FDA greenlit TOCILIZUMAB-ANOH (AVTOZMA) via BLA 761498 on Jan 21, marking rare original new drug entry with portfolio diversification potential.

Three ANDA approvals for SERTRALINE HYDROCHLORIDE (APPCO, UMEDICA, NOVITIUM) on Jan 20 accelerate generic penetration in high-volume antidepressant market.

3 simultaneous SERTRALINE HYDROCHLORIDE ANDA approvals intensify pricing erosion in commoditized SSRI generics.

All 7 ANDAs under standard review with no designations expose sponsors to typical generic pricing pressures absent differentiation.

Celltrion's original BLA enables label expansion or new indications for TOCILIZUMAB-ANOH, bolstering biosimilar/revenue diversification.

Routine ANDA approvals provide low-cost market entry ramps for 7 sponsors in established drugs like SACUBITRIL, MIRABEGRON.

7/8 records are standard ANDA generics, reflecting efficient FDA throughput for mature molecules but no premium innovation.

Single BLA for TOCILIZUMAB-ANOH breaks generic dominance, hinting at biosimilar momentum absent in data.

{"entity"=>"Celltrion Inc", "reason"=>"Sole bullish original BLA; unspecified indication caps assessment", "trigger"=>"label details or sales guidance release"}

{"entity"=>"SERTRALINE HYDROCHLORIDE generics (APPCO, UMEDICA, NOVITIUM)", "reason"=>"43% of approvals (3/7 ANDAs) concentrated here, signaling competition peak", "trigger"=>"pricing declines >10% or share shifts"}